You are here:

Home
NICE Guidance
Conditions and diseases
Diabetes and other endocrinal, nutritional and metabolic conditions
Diabetes

Ranibizumab for treating diabetic macular oedema

Technology appraisal guidance
Reference number: TA274
Published: 27 February 2013
Last updated: 26 October 2023

Guidance
Tools and resources
Information for the public
History

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): consultee and commentator comments on the ACD

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Novartis
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Diabetes UK
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): RNIB
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): RCP and ABCD
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): CSAS
Macular oedema (diabetic) - ranibizumab (rapid review of TA237): Department of Health

This page was last updated: 28 December 2012